RBC Capital on 4D Molecular Therapeutics (FDMT): 'Story Remains On Track for Late-Stage Execution in wAMD and Pipeline Growth' Jan 7, 2026 10:22AM
4D Molecular Therapeutics (FDMT) PT Raised to $32 at RBC Capital Nov 11, 2025 08:39AM
RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT) Oct 21, 2025 09:11AM
4DMT to Participate in Upcoming Investor Conferences May 5, 2025 08:00AM
4DMT to Participate in Upcoming Investor Conferences Mar 27, 2025 08:00AM


Jul 22, 2024 06:24AM RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
Jul 17, 2024 01:19PM 4D Molecular Therapeutics tumbles following mid-stage clinical study results
Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview
Jun 26, 2024 05:40AM RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
Apr 15, 2024 06:29AM 4D Molecular Therapeutics (FDMT) PT Raised to $40 at RBC Capital